Literature DB >> 11175303

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a TNFRSF1A mutation with reduced penetrance.

E Aganna1, I Aksentijevich, G A Hitman, D L Kastner, A I Hoepelman, F D Posma, E J Zweers, M F McDermott.   

Abstract

Mutations of the tumor necrosis factor receptor 1 (TNFRSF1A) gene underly susceptibility to a subset of autosomal dominant recurrent fevers (ADRFs). We report on a two-generation six-member Dutch family in which a novel R92P mutation and reduced plasma TNFRSF1A levels were found in all the children, including two who are unaffected. However, only the daughter proband and father exhibited a typical TNF-receptor associated periodic syndrome (TRAPS) phenotype. PCR-RFLP analysis revealed that the mutation was not present in 120 control chromosomes from unaffected Dutch individuals. As this R92P mutation is present in two unaffected carriers it appears to be less penetrant than previously reported TNFRSF1A mutations involving cysteine residues in the extracellular domains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11175303     DOI: 10.1038/sj.ejhg.5200573

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  9 in total

1.  The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.

Authors:  I Aksentijevich; J Galon; M Soares; E Mansfield; K Hull; H H Oh; R Goldbach-Mansky; J Dean; B Athreya; A J Reginato; M Henrickson; B Pons-Estel; J J O'Shea; D L Kastner
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

Review 2.  Tumor necrosis factor-associated periodic syndrome in adults.

Authors:  Sharika Gopakumar Menon; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-09-23       Impact factor: 2.631

3.  Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene.

Authors:  N Ravet; S Rouaghe; C Dodé; J Bienvenu; J Stirnemann; P Lévy; M Delpech; G Grateau
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

Review 4.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

5.  Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept.

Authors:  P D Arkwright; M F McDermott; S M Houten; J Frenkel; H R Waterham; E Aganna; L J Hammond; R M Mirakian; P I Tomlin; P I Vijaydurai; A J Cant
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 6.  [Periodic fever syndromes].

Authors:  C Huemer; M Huemer
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

7.  Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family.

Authors:  Koichi Kusuhara; Akihiko Nomura; Futoshi Nakao; Toshiro Hara
Journal:  Eur J Pediatr       Date:  2003-11-11       Impact factor: 3.183

8.  Somatic mosaicism in adult-onset TNF receptor-associated periodic syndrome (TRAPS).

Authors:  Apostolos Kontzias; Samaneh K Zarabi; Cassandra Calabrese; Yan Wang; LuAnn Judis; QingPing Yao; Yu-Wei Cheng
Journal:  Mol Genet Genomic Med       Date:  2019-07-10       Impact factor: 2.183

9.  Involvement of the same TNFR1 residue in mendelian and multifactorial inflammatory disorders.

Authors:  Isabelle Jéru; Serge Charmion; Emmanuelle Cochet; Bruno Copin; Philippe Duquesnoy; Maria Teresa Mitjavila Garcia; Gaëlle Le Borgne; Pascal Cathebras; Jacques Gaillat; Sonia Karabina; Catherine Dodé; Peter Lohse; Véronique Hentgen; Serge Amselem
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.